Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy
- 11 April 2011
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 108 (17), 7142-7147
- https://doi.org/10.1073/pnas.1016569108
Abstract
Trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor-2 (HER2/ErbB-2), has become the mainstay of treatment for HER2-positive breast cancer. Nevertheless, its exact mechanism of action has not been fully elucidated. Although several studies suggest that Fc receptor-expressing immune cells are involved in trastuzumab therapy, the relative contribution of lymphocyte-mediated cellular cytotoxicity and antitumor cytokines remains unknown. We report here that anti-ErbB-2 mAb therapy is dependent on the release of type I and type II IFNs but is independent of perforin or FasL. Our study thus challenges the notion that classical antibody-dependent, lymphocyte-mediated cellular cytotoxicity is important for trastuzumab. We demonstrate that anti-ErbB-2 mAb therapy of experimental tumors derived from MMTV-ErbB-2 transgenic mice triggers MyD88-dependent signaling and primes IFN-γ-producing CD8+ T cells. Adoptive cell transfer of purified T cell subsets confirmed the essential role of IFN-γ-producing CD8+ T cells. Notably, anti-ErbB-2 mAb therapy was independent of IL-1R or IL-17Ra signaling. Finally, we investigated whether immunostimulatory approaches with antibodies against programmed death-1 (PD-1) or 41BB (CD137) could be used to capitalize on the immune-mediated effects of trastuzumab. We demonstrate that anti-PD-1 or anti-CD137 mAb can significantly improve the therapeutic activity of anti-ErbB-2 mAb in immunocompetent mice.Keywords
This publication has 34 references indexed in Scilit:
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive ImmunityCancer Cell, 2010
- Refining Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: T Stands for Trastuzumab, Tumor Size, and Treatment StrategyJournal of Clinical Oncology, 2009
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast CancerJournal of Clinical Oncology, 2009
- The Impact of HER2/neuExpression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Clinical Cancer Research, 2009
- Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune responseProceedings of the National Academy of Sciences of the United States of America, 2008
- Antibody association with HER-2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCsJCI Insight, 2008
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesisProceedings of the National Academy of Sciences of the United States of America, 2008
- CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancerBreast Cancer Research, 2007
- Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast CancerAnnals of Surgical Oncology, 2006